The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?
Featured:
Uwe PlatzbeckerThe MDS Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, during the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting. We asked, “What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?”
What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?
Platzbecker discusses the open-label, randomized, controlled, phase III COMMANDS trial (NCT03682536), previously covered by the MDS Hub, which investigated luspatercept versus epoetin alfa for the treatment of anemia in transfusion-dependent, erythropoiesis-stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). He highlights the association of treatment with luspatercept and improved transfusion independence found in the trial, and discusses the impact of these results on clinical practice.
